Would you add immunotherapy to FOLFOX if the patient is not a FLOT candidate for neoadjuvant gastric cancer, extrapolating data from the MATTERHORN study?   

While it is always somewhat perilous to extrapolate from a proper study to lesser situations, this seems quite reasonable. It seems highly unlikely that the removal of Taxotere from a fluoropyrimidine-oxaliplatin-based regimen would render immunotherapy less effective in gastric cancer. In the MATTE...